A method to induce hen egg lysozyme-specific humoral immune tolerance in mice by pre-exposition with the protein's oligomers

[1]  Zuben E Sauna,et al.  Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins. , 2018, Trends in biotechnology.

[2]  Z. Sauna,et al.  Immunogenicity assessment during the development of protein therapeutics , 2018, The Journal of pharmacy and pharmacology.

[3]  Ross A Soo,et al.  De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.

[4]  Elissa M. Hudspeth,et al.  Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease , 2017, Human vaccines & immunotherapeutics.

[5]  Z. Su,et al.  Aggregation and antigenicity of virus like particle in salt solution--A case study with hepatitis B surface antigen. , 2015, Vaccine.

[6]  U. Rinas,et al.  Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  Kunihiro Hattori,et al.  Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization , 2010, Nature Biotechnology.

[8]  M. Tsuchiya,et al.  Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization , 2010, Anti-cancer drugs.

[9]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[10]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[11]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[12]  D. Keskin,et al.  Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice , 2008, Proceedings of the National Academy of Sciences.

[13]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[14]  R. Liblau,et al.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance , 2007, Proceedings of the National Academy of Sciences.

[15]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[16]  Guido Cappuccilli,et al.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Schellekens,et al.  Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview , 2005, Annals of the New York Academy of Sciences.

[18]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[20]  J. Strominger,et al.  Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Richard A. Flavell,et al.  Defective Antigen Processing in GILT-Free Mice , 2001, Science.

[22]  T. So,et al.  The molecular weight ratio of monomethoxypolyethylene glycol (mPEG) to protein determines the immunotolerogenicity of mPEG proteins. , 1999, Protein engineering.

[23]  T. So,et al.  Extended blood half-life of monomethoxypolyethylene glycol-conjugated hen lysozyme is a key parameter controlling immunological tolerogenicity , 1999, Cellular and Molecular Life Sciences CMLS.

[24]  Ueda,et al.  Tolerogenic activity of polyethylene glycol‐conjugated lysozyme distinct from that of the native counterpart , 1998, Immunology.

[25]  T. So,et al.  Prevention of collagen‐induced arthritis (CIA) by treatment with polyethylene glycol‐conjugated type II collagen; distinct tolerogenic property of the conjugated collagen from the native one , 1997, Clinical and experimental immunology.

[26]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[27]  M. Hershfield,et al.  PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. , 1995, Clinical immunology and immunopathology.

[28]  D. Abramowicz,et al.  The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes , 1992, The Journal of experimental medicine.

[29]  T. Imoto,et al.  Preparation and properties of a lysozyme derivative in which two domains are cross-linked intramolecularly between Trp62 and Asp101. , 1991, Journal of biochemistry.

[30]  C. Verhoest,et al.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. , 1984, Cancer biochemistry biophysics.

[31]  L. Montesano,et al.  Disuccinimidyl suberate cross-linked ricin does not inhibit cell-free protein synthesis. , 1982, Biochemical and biophysical research communications.

[32]  D.Sc. S. William A. Gunn M.D.,et al.  On Vaccination , 1802, The Medical and physical journal.

[33]  S Porter,et al.  Human immune response to recombinant human proteins. , 2001, Journal of pharmaceutical sciences.

[34]  C. Goodnow.  Transgenic mice and analysis of B-cell tolerance. , 1992, Annual review of immunology.